9668 Federal Register / Vol. 77, No. 33 / Friday, February 17, 2012 / Notices 

For Further Information 

To request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Dr. Sarah L. 

Glavin, Deputy Director, Office of 

Science Policy, Analysis and 

Communication, National Institute of 

Child Health and Human Development, 

31 Center Drive Room 2A18, Bethesda, 

Maryland, 20892, or call non-toll free 

number (301) 496–1877 or Email your 

request, including your address to 

glavins@mail.nih.gov. 

Comments Due Date 

Comments regarding this information 

collection are best assured of having 

their full effect if received within 60 

days of the date of this publication. 

Dated: February 10, 2012. 

Sarah L. Glavin, 

Deputy Director, Office of Science Policy, 

Analysis and Communications, National 

Institute of Child Health and Human 

Development. 

[FR Doc. 2012–3809 Filed 2–16–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Selective Inhibitors of Polo-Like Kinase 

1 (PLK1) Polo-Box Domains as Potential 

Anticancer Agents 

Description of Technology: PLK1 is a 

regulator of cell growth that represents 

a new target for anticancer therapeutic 

development. High expression of PLK1 

has been associated with several types 

of cancer (e.g., breast cancer, prostate 

cancer, ovarian cancer, non-small cell 

lung carcinoma). Inhibiting PLK1 could 

be an effective treatment for cancer 

patients without significant side-effects. 

Available for licensing are synthetic 

peptides with the ability to bind to pololike kinase 1 (PLK1) polo-box domains 

(PBDs) with selectivity and nanomolar 

affinity and induce apoptosis in cancer 

cells. By inhibiting the functions of 

PLK1, these peptides could serve as 

potential anti-cancer therapies. This 

technology is related to and an 

extension of HHS technology reference 

E–181–2009. 

Potential Commercial Applications: 

• New anticancer therapies that 

specifically target PLK1. 

• Platform for the development of 

further improved PLK1 inhibitors. 

Competitive Advantages: 

• High PBD binding affinity. 

• High binding selectivity. 

Development Stage: Early-stage. 

Inventors: Terrence R. Burke, Jr. (NCI), 

et al. 

Publications: 

1. Liu F, et al. Serendipitous 

alkylation of a Plk1 ligand uncovers a 

new binding channel. Nat Chem Biol. 

2011 Jul 17;7(9):595–601. [PMID 

21765407] 

2. Qian W, et al. Investigation of 

unanticipated alkylation at the N(pi) 

position of a histidyl residue under 

Mitsunobu conditions and synthesis of 

orthogonally protected histidine 

analogues. J Org Chem. 2011 Nov 

4;76(21):8885–8890. [PMID 21950469] 

Intellectual Property: HHS Reference 

No. E–053–2012/0—U.S. Provisional 

Application No. 61/588,470 filed 19 Jan 

2012. 

Related Technology: HHS Reference 

No. E–181–2009/3—U.S. Provisional 

Application No. 61/474,621 filed 12 Apr 

2011. 

Licensing Contact: Patrick McCue, 

Ph.D.; 301–435–5560; 

mccuepat@mail.nih.gov. 

Influenza Vaccine 

Description of Technology: It has been 

shown that the fusion peptide, a 

sequence comprised of fourteen amino 

acids at the N-terminal of the influenza 

hemagglutinin 2 protein is conserved 

among A and B influenza viruses. 

Monoclonal antibodies against this 

peptide are capable of binding all 

influenza virus HA proteins and inhibit 

viral growth by impeding the fusion 

process between the virus and the target 

cell. This application claims 

immunogenic conjugates comprising the 

fusion peptide region linked to a carrier 

protein. In preclinical studies, these 

conjugates were immunogenic and 

induced booster responses. The induced 

antibodies bound to the recombinant 

HA protein. This methodology of 

linking the highly conserved fusion 

peptide region to a carrier protein can 

broaden the protective immune 

response to include influenza A and B 

virus strains. This would eliminate the 

need for annual influenza vaccination. 

Potential Commercial Applications: 

• Influenza vaccines 

• Influenza diagnostics 

• Research tools 

Competitive Advantages: 

• Universal influenza vaccine 

• Efficient manufacturing process 

• May eliminate need for yearly 

influenza vaccination 

Development Stage: 

• Pre-clinical 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Joanna Kubler-Kielb, Jerry 

M. Keith, Rachel Schneerson (NICHD). 

Intellectual Property: HHS Reference 

No. E–271–2011/0—U.S. Provisional 

Application No. 61/541,942 filed 30 Sep 

2011. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301–435–4646; ps193c@nih.gov. 

Collaborative Research Opportunity: 

The NICHD is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize conjugate influenza 

vaccines comprising fusion peptide 

region. For collaboration opportunities, 

please contact Joseph Conrad, Ph.D., J.D. 

at 301–435–3107 or 

jmconrad@mail.nih.gov. 

ACSF3-Based Diagnostics and 

Therapeutics for Combined Malonic 

and Methylmalonic Aciduria 

(CMAMMA) and Other Metabolic 

Disorders 

Description of Technology: Combined 

malonic and methylmalonic aciduria 

(CMAMMA) is a metabolic disorder in 

which malonic acid and methylmalonic 

acid, key intermediates in fatty acid 

metabolism, accumulate in the blood 

and urine. This disorder is often 

undetected until symptoms manifest, 

which can include developmental 

delays and a failure to thrive in 

children, and psychiatric and 

neurological disorders in adults. Once 

thought to be a very rare disease, 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 77, No. 33 / Friday, February 17, 2012 / Notices 9669 

CMAMMA is now thought to be one of 

the most common forms of 

methylmalonic acidemia, and perhaps 

one of the most common inborn errors 

of metabolism, with a predicted 

incidence of one in 30,000. 

Investigators at the National Human 

Genome Research Institute (NHGRI) 

have identified the genetic cause of 

CMAMMA, an enzyme encoded by the 

ACSF3 (Acyl-CoA Synthetase Family 

Member 3) gene. This enzyme is located 

in the mitochondrion, and appears to be 

a methylmalonyl-CoA and malonyl-CoA 

synthetase, which catalyzes the first 

step of intra-mitochondrial fatty acid 

synthesis. As such, this discovery may 

not only be critical for the development 

of diagnostic tools and treatments for 

CMAMMA, but also holds promise for 

the treatment of other related metabolic 

disorders. 

Potential Commercial Applications: 

• Diagnosis of CMAMMA or other 

metabolic diseases. 

• Therapies for CMAMMA or other 

metabolic diseases, such as lipoic acid 

administration, gene therapy or enzyme 

replacement therapy. 

Competitive Advantages: 

• Mutation of ACSF3 has been shown 

to be the genetic cause of CMAMMA, 

and there are no existing methods to 

diagnose this disorder. 

• Therapies based on ACSF3 may be 

applicable to a variety of metabolic 

disorders. 

Development Stage: 

• In vivo data available (animal). 

• In vivo data available (human). 

Inventors: Charles P. Venditti, Leslie 

G. Biesecker, Jennifer L. Sloan, Jennifer 

J. Johnston, Eirini Manoli, Randy J. 

Chandler (all of NHGRI). 

Publication: Sloan JL, et al. Exome 

sequencing identifies ACSF3 as a cause 

of combined malonic and 

methylmalonic aciduria. Nat Genet. 

2011 Aug 14;43(9):883–886. [PMID 

21841779] 

Intellectual Property: HHS Reference 

No. E–209–2011/0—U.S. Provisional 

Application No. 61/504,030 filed 01 Jul 

2011. 

Licensing Contact: Tara L. Kirby, 

Ph.D.; 301–435–4426; 

tarak@mail.nih.gov. 

Antagonists of the Hedgehog Pathway 

as Therapeutics for the Treatment of 

Heterotopic Ossification, Vascular 

Calcification, and Pathologic 

Mineralization 

Description of Technology: 

Heterotopic ossification (HO) results 

from osteoid formation of mature 

lamellar bone in soft tissue sites outside 

the skeletal periosteum (skeletal 

system), most commonly around 

proximal limb joints. HO can also be 

caused by genetic diseases such as 

progressive osseous heteroplasia (POH) 

and fibrodysplasia ossificans 

progressiva (FOP). Currently, all forms 

of HO lack adequate treatments and 

definite cure. Vascular calcification is a 

complex process that involves 

biomineralization and resembles 

osteogenesis. It is exacerbated during 

such conditions as diabetes, 

osteoporosis, menopause, hypertension, 

metabolic syndrome, chronic kidney 

disease, and end stage renal disease. In 

the present technology, the inventors 

describe novel methods for preventing 

or treating HO and vascular calcification 

using one or more antagonists of the 

Hedgehog pathway. The inventors, 

using both in vitro (limb culture 

experiments) and in vivo studies using 

Prx1-cre; Gsf/f mice model discovered 

that the antagonists of the Hedgehog 

pathway prevent formation of HO. The 

inventors also observed that Prx1-cre; 

Gsf/f mice developed calcification or 

mineralization around their blood 

vessels, and treatment with Hedgehog 

antagonists reduced mineralization 

throughout the body of these mice, 

including regions around the blood 

vessels, as observed by mineral staining. 

The antagonists that can be used to 

develop effective therapeutics include 

zerumbone epoxide, arcyriaflavin C, 5,6- 

dihyroxyarcyriaflavin A, physalin F, 

physalin B, arsenic trioxide (ATO), 

sodium arsenite, etc. 

Potential Commercial Applications: 

Development of therapeutics for 

heterotopic ossification, vascular 

calcification, and pathologic 

mineralization. 

Competitive Advantages: Several 

clinically tested and FDA-approved 

Hedgehog antagonists are currently 

available and these compounds will 

expedite the commercial development 

of this technology. 

Development Stage: 

• Early-stage. 

• Pre-clinical. 

• In vitro data available. 

• In vivo data available (animal). 

Inventors: Yingzi Yang and Jean 

Regard (NHGRI). 

Intellectual Property: HHS Reference 

No. E–116–2011/0—U.S. Provisional 

Application No. 61/504,041 filed 01 Jul 

2011. 

Licensing Contact: Suryanarayana 

(Sury) Vepa, Ph.D.; 301–435–5020; 

vepas@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Human Genome Research 

Institute (NHGRI) is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize antagonists of the 

Hedgehog pathway for treatment of 

ossification and calcification disorders. 

For collaboration opportunities, please 

contact Claire T. Driscoll at 301–594– 

2235 or cdriscoll@mail.nih.gov. 

A Novel Treatment for Malarial 

Infections 

Description of Technology: The 

inventions described herein are 

antimalarial small molecule inhibitors 

of the plasmodial surface anion channel 

(PSAC), an essential nutrient acquisition 

ion channel expressed on human 

erythrocytes infected with malaria 

parasites. These inhibitors were 

discovered by high-throughput 

screening of chemical libraries and 

analysis of their ability to kill malaria 

parasites in culture. Two separate 

classes of inhibitors were found to work 

synergistically in combination against 

PSAC and killed malaria cultures at 

markedly lower concentrations than 

separately. These inhibitors have high 

affinity and specificity for PSAC and 

have acceptable cytotoxicity profiles. 

Preliminary in vivo testing of these 

compounds in a mouse malaria model is 

currently ongoing. 

Potential Commercial Applications: 

Treatment of malarial infections. 

Competitive Advantages: 

• Novel drug treatment for malarial 

infections. 

• Synergistic effect of these 

compounds on PSAC. 

Development Stage: 

• In vitro data available. 

• In vivo data available (animal). 

Inventor: Sanjay A. Desai (NIAID). 

Publications: 

1. Kang M, et al. Malaria parasites are 

rapidly killed by dantrolene derivatives 

specific for the plasmodial surface anion 

channel. Mol. Pharmacol. 2005 

Jul;68(1):34–40. [PMID 15843600] 

2. Desai SA, et al. A voltagedependent channel involved in nutrient 

uptake by red blood cells infected with 

the malaria parasite. Nature. 2000 Aug 

31;406(6799):1001–1005. [PMID 

10984055] 

Patent Status: HHS Reference No. E– 

202–2008/0—U.S. Patent Application 

No. 13/055,104 filed 20 Jan 2011; 

various international patent 

applications. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID Office of Technology 

Development is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize antimalarial drugs that 

mstockstill on DSK4VPTVN1PROD with NOTICES

9670 Federal Register / Vol. 77, No. 33 / Friday, February 17, 2012 / Notices 

target PSAC or other parasite-specific 

transporters. For collaboration 

opportunities, please contact Dana Hsu 

at 301–496–2644. 

Dated: February 13, 2012. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2012–3824 Filed 2–16–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Alzheimer’s 

Prevention. 

Date: March 1, 2012. 

Time: 5 p.m. to 8 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites, Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: William Cruce, Ph.D., 

Scientific Review Officer, National Institute 

on Aging, Scientific Review Branch, Gateway 

Building 2C–212, 7201 Wisconsin Ave., 

Bethesda, MD 20814, 301–402–7704, 

crucew@nia.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Contract 

ABC. 

Date: March 9, 2012. 

Time: 12 p.m. to 1:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Suite 2C212, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Alicja L. Markowska, 

Ph.D., DSC, Scientific Review Branch, 

National Institute on Aging, 7201 Wisconsin 

Avenue, Suite 2C212, Bethesda, MD 20892, 

301–496–9666, markowsa@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Datasets in 

Aging. 

Date: April 2–3, 2012. 

Time: 9 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel, 8120 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Rebecca J. Ferrell, Ph.D., 

Scientific Review Officer, National Institute 

on Aging, Gateway Building Rm. 2C212, 7201 

Wisconsin Avenue, Bethesda, MD 20892, 

301–402–7703, ferrellrj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: February 10, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–3821 Filed 2–16–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Novel Technologies for Powering Ventricular 

Assist Devices. 

Date: March 8, 2012. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Stephanie J Webb, Ph.D., 

Scientific Review Officer, Review Branch/ 

DERA, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7196, 

Bethesda, MD 20892, 301–435–0291, 

stephanie.webb@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Pulmonary Vascular—Right Ventricular Axis 

Research Program. 

Date: March 9, 2012. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Garden Inn, 7301 Waverly 

Street, Bethesda, MD 20814. 

Contact Person: YingYing Li-Smerin, MD, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6701 Rockledge 

Drive, Room 7184, Bethesda, MD 20892– 

7924, 301–435–0277, lismerin@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 10, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–3826 Filed 2–16–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK UDA 

Contract Proposal Review. 

Date: March 16, 2012. 

Time: 2:30 p.m. to 4 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Xiaodu Guo, MD, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 761, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES